Sarah E. Dorff

1.3k total citations
5 papers, 364 citations indexed

About

Sarah E. Dorff is a scholar working on Genetics, Hematology and Surgery. According to data from OpenAlex, Sarah E. Dorff has authored 5 papers receiving a total of 364 indexed citations (citations by other indexed papers that have themselves been cited), including 2 papers in Genetics, 2 papers in Hematology and 1 paper in Surgery. Recurrent topics in Sarah E. Dorff's work include Acute Myeloid Leukemia Research (2 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers) and HER2/EGFR in Cancer Research (1 paper). Sarah E. Dorff is often cited by papers focused on Acute Myeloid Leukemia Research (2 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers) and HER2/EGFR in Cancer Research (1 paper). Sarah E. Dorff collaborates with scholars based in United States. Sarah E. Dorff's co-authors include Rosane Charlab, Richard Pazdur, Kirsten B. Goldberg, Julia A. Beaver, Vicky Hsu, Shenghui Tang, Pengfei Song, Tiffany K. Ricks, Marc R. Theoret and Lijun Zhang and has published in prestigious journals such as Clinical Cancer Research and Clinical Pharmacology & Therapeutics.

In The Last Decade

Sarah E. Dorff

5 papers receiving 362 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sarah E. Dorff United States	4	177	117	96	60	60	5	364
Eric Cheung United States	11	244 1.4×	96 0.8×	79 0.8×	39 0.7×	24 0.4×	21	498
Timothy M. Pierpont United States	6	145 0.8×	132 1.1×	75 0.8×	42 0.7×	20 0.3×	10	376
Patrick Chun United States	9	243 1.4×	142 1.2×	41 0.4×	28 0.5×	36 0.6×	19	364
Soumi Lahiri United States	8	242 1.4×	159 1.4×	90 0.9×	22 0.4×	35 0.6×	9	361
Rodrigo Ruiz-Soto United States	9	186 1.1×	174 1.5×	66 0.7×	25 0.4×	37 0.6×	19	408
T. Brümmendorf Germany	9	138 0.8×	82 0.7×	44 0.5×	48 0.8×	32 0.5×	16	283
Laurence Hatteville France	8	295 1.7×	70 0.6×	92 1.0×	10 0.2×	74 1.2×	10	384
Andrew Cannon United States	10	245 1.4×	252 2.2×	51 0.5×	57 0.9×	79 1.3×	24	501
Maksim Yezhelyev Germany	7	183 1.0×	245 2.1×	28 0.3×	51 0.8×	56 0.9×	7	429
Radek Jakša Czechia	10	146 0.8×	138 1.2×	19 0.2×	22 0.4×	47 0.8×	27	326

Countries citing papers authored by Sarah E. Dorff

Since Specialization

Citations

This map shows the geographic impact of Sarah E. Dorff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah E. Dorff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah E. Dorff more than expected).

Fields of papers citing papers by Sarah E. Dorff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah E. Dorff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah E. Dorff. The network helps show where Sarah E. Dorff may publish in the future.

Co-authorship network of co-authors of Sarah E. Dorff

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah E. Dorff. A scholar is included among the top collaborators of Sarah E. Dorff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah E. Dorff. Sarah E. Dorff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Woods, Ashley, Dianne Pulte, Jonathon Vallejo, et al.. (2025). FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation. Clinical Cancer Research. 31(17). 3613–3617. 1 indexed citations

2.

Chang, Elaine, Chana Weinstock, Lijun Zhang, et al.. (2020). FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research. 27(4). 922–927. 135 indexed citations

3.

Fashoyin‐Aje, Lola A., Christy Osgood, Joyce Cheng, et al.. (2020). FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer. Clinical Cancer Research. 27(7). 1850–1854. 114 indexed citations

4.

Norsworthy, Kelly J., Lola Luo, Vicky Hsu, et al.. (2019). FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation. Clinical Cancer Research. 25(11). 3205–3209. 102 indexed citations

5.

Schuck, Robert N., Janet Woodcock, Issam Zineh, et al.. (2018). Considerations for Developing Targeted Therapies in Low‐Frequency Molecular Subsets of a Disease. Clinical Pharmacology & Therapeutics. 104(2). 282–289. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact